No Detail Found!

Outcome of GPLLB/LLLA inhibitors in totally occluded coronary artery in patients presenting with acute myocardial infarction late for thrombolysis or primary percutaneous coronary intervention

Author(s)
Fahad Khalid NUST School of Health Sciences, Islamabad-Pakistan
Muhammad Fareed Khan Poonch Medical College, AJK, Pakistan.
Wahab Anwar Armed Forces Institute of Cardiology, Rawalpindi-Pakistan
Muhammad Fasiullah Khan Pakistan Institute of Medical Sciences, Islamabad-Pakistan
Muhammad Hasnain Iqbal HBS Medical and Dental College, Islamabad-Pakistan
Naveed Yaqoob NUST School of Health Sciences, Islamabad-Pakistan
Abstract
Background: Acute coronary ischemia is one of the most fatal cardiovascular events, presenting with tremendously high morbidity and mortality, especially in cases involving a completely occluded artery, leading to acute myocardial infarction (AMI). The study aimed to ascertain the efficacy and safety of glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitors in Pakistani patients who present late for thrombolysis or primary percutaneous coronary intervention (PCI). Method: The trial was conducted at a tertiary care hospital in Islamabad, including 200 patients, with GP IIb/IIIa inhibitors used in 40% of infarct-related artery (IRA) cases. Results: The analysis revealed that GP IIb/IIIa inhibitors reduced major adverse cardiac events (MACE) by 9%, recurrent myocardial infarction (MI) by 7.5%, and improved thrombus resolution by 25%, as well as myocardial salvage by 12%. However, there was a higher rate of bleeding complications (p<.05) associated with their use. No other significant adverse events, such as in-hospital mortality, length of stay, or renal complications, were identified. Conclusions: These results suggest that GP IIb/IIIa inhibitors should not be used as a one-size-fits-all therapy. Proper patient selection, along with robust monitoring under doseadjusted Eptifibatide or Tirofiban infusion regimens to target coagulation levels appropriately, is crucial. Although this treatment could be valuable in managing AMI, particularly in regions where advanced cardiac care is less accessible, further large-scale, multicenter studies are needed to determine its long-term safety and efficacy. This study provides a framework for further investigations into the use of GP IIb/IIIa inhibitors in similar patient populations.
Publication Details
Page(s) 803-807
DOI DOI not available
Published Journal: Journal of Ayub Medical College, Volume: 36, Issue: 4, Year: 2024

Request the full text from PASTIC

Keywords
Acute Myocardial Infarction, thrombolysis, Primary percutaneous coronary intervention, Renal Complication, GP IIb/IIIa inhibitors
References
Antman EM,Anbe DT,Armstrong PW,Bates ER,Green LA,Hand M .2004 .ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction-executive summary. Circulation, 110(5) : 588-636.
Niccoli G,Scalone G,Lerman A,Crea F .2009 .Coronary microvascular obstruction in acute myocardial infarction. Eur Heart J, 30(24) : 2886-93.
Topol EJ,Moliterno DJ,Herrmann HC,Powers ER,Grines CL,Cohen DJ .2001 .Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med, 344(25) : 1888-94.
.1994 .Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med, 330(14) : 956-61.
.1998 .Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med, 339(7) : 436-43.
De Luca G,Suryapranata H,Stone GW,Antoniucci D,Tcheng JE,Neumann FJ .2009 .Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA, 301(13) : 1365-73.
.2001 .Comparison of abciximab and tirofiban for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med, 344(25) : 1888-94.
Stone GW,Grines CL,Cox DA,Garcia E,Tcheng JE,Griffin JJ .2001 .Comparison of angioplasty with stenting with and without abciximab for acute myocardial infarction. N Engl J Med, 344(7) : 493-501.
Henriques JP,Zijlstra F,Hof AW,de Boer MJ,Dambrink JH,Gosselink AT .2003 .Angiographic no-reflow phenomenon in acute myocardial infarction: the TIMI frame count and myocardial blush grade identify different forms of distal embolization. J Am Coll Cardiol, 42(11) : 1772-7.
Zeymer U,Vogt A,Zahn R,Weber M,Tebbe U,Gottwik M .2003 .Predictors of no reflow after primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction. Int J Cardiol, 90(1) : 119-25.
Gershlick AH,More R,Banning AP,Dissanayake A,Rickards A .2005 .A randomized, placebo-controlled trial of rescue angioplasty after failed thrombolysis: The Middlesbrough Early Revascularisation to Limit Infarction (MERLIN) trial. J Am Coll Cardiol, 46(6) : 827-36.
Jolly SS,Yusuf S,Cairns J,Meeks B,Pogue J,Rokoss MJ .2009 .Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomized, parallel group, multicentre trial. Lancet, 377(9775) : 1409-20.
Tamhane UU,Gurm HS .2008 .The chimeric monoclonal antibody abciximab: a systematic review of its safety in contemporary practice. Expert Opin Drug Saf, 7(6) : 809-19.
Dunn CJ,Foster RH .1999 .Abciximab: a pharmacoeconomic review of its use in percutaneous coronary revascularisation. Pharmacoeconomics, 16 : 711-41.
'Connor O,Platek CM,McCullough AE,PA AE .2003 .Safety profile of GP IIb/IIIa inhibitors: a review. Circulation, 107(23) : 2924-9.
Stone GW,McLaurin BT,Cox DA .2004 .The safety and efficacy of GP IIb/IIIa inhibitors: a comprehensive review. N Engl J Med, 350(24) : 2470-9.
0

Citations

0

Downloads

65

Views